Almac has successfully completed the Health Sciences Authority (HSA) inspection of its new Asia Pacific headquarters in Singapore, having met standards of safety, quality and efficacy for GMP certification. 
 
The newly opened facility expands Almac’s suite of clinical trial primary and secondary packaging, distribution, technology and consultation solutions offered in the region. The Singapore facility has full-service equipment including primary packaging rooms, secondary packaging areas, frozen storage, label control room, a Just-in-Time (JIT) labelling suite and non-GMP storage area.
 
 “Asia Pacific is a vital region for us, as currently 23% of global clinical trials for new pharmaceutical products are being conducted here. By basing our regional headquarters and operations in Singapore, we are better equipped to support our Asia-based clients in their own time zone and languages,” said Dr. Robert Dunlop, president and managing director of Almac’s Clinical Services business unit. “With the opening of our new Singapore facility, we are directly supporting studies run by regional and global pharmaceutical firms by providing critical manufacturing, packaging, supply chain management and Interactive Response Technology (IRT) support services in Asia Pacific.”